BDMDWNasdaqSurgical & Medical Instruments & ApparatusUS GAAP · USD

Baird Medical Investment Holdings Ltd

Baird Medical Investment Holdings Ltd is a U.S.-listed medical device company focused on minimally invasive ablation technologies for solid tumors. Its business centers on microwave ablation systems and related products used in clinical settings, with operations and corporate functions rooted in China and commercial activity reaching multiple international markets.

Kysy yhtiöstä
Liikevaihto22,5milj. USD
−39,2 %v/v
Liikevoitto (EBIT)−25,6milj. USD
−267,4 %v/v
EBIT-marginaali−113,7%
−155,1 %-yks.v/v
Nettotulos−27,3milj. USD
−319,0 %v/v
Vapaa kassavirta−1,4milj. USD
+84,9 %v/v

Tilikausi 2025 · muutos edellisvuodesta

Kehitys 2022–2025

−40−2002040milj. USD2022: 35 milj. USD2022: EBIT 14 milj. USD20222023: 31 milj. USD2023: EBIT 12 milj. USD20232024: 37 milj. USD2024: EBIT 15 milj. USD20242025: 23 milj. USD2025: EBIT −26 milj. USD202523−26
LiikevaihtoLiikevoitto (EBIT)
Kysy Clarifolta: Baird Medical Investment Holdings Ltd

Liiketoiminta

Osuus liikevaihdosta
Microwave ablation systems70 %

Energy-based devices used for minimally invasive tissue ablation in clinical procedures.

Ablation accessories and consumables15 %

Procedure-related items sold alongside the main ablation platforms and used in treatment workflows.

Emerging ablation technologies10 %

Development-stage IRE-based and other ablation products intended to broaden the portfolio.

Robotic and AI-assisted systems5 %

Next-generation robotic ablation solutions under development for image-guided procedures.

Tuotteet

Raportoitu · osuus liikevaihdosta
76,4%23,6%FY2025100 %
  • Microwave Ablation Needles76,4 %
  • Microwave Ablation Therapeutic Apparatus23,6 %

Lähde: 20-F/A FY2025, yhtiön tuotelinjoittain raportoima liikevaihto (SEC XBRL). Osuudet on laskettu näytetyistä riveistä ja ne summautuvat 100 %:iin.

Asiakkaat

Baird Medical sells primarily to hospitals, medical centers, and private practice groups that perform minimally invasive tumor and thyroid procedures. Its products are used by interventional physicians who need image-guided ablation tools for soft tissue treatment, especially in settings that value lower-invasiveness alternatives to surgery. The company also addresses institutional buyers that adopt new technologies through clinical evaluation and physician preference.

Hospitals and academic medical centers

Buy MWA systems and related tools for interventional oncology and thyroid procedures.

Private practice groups

Purchase ablation platforms for outpatient and specialty-care procedures.

Interventional physicians

Influence purchasing by selecting devices that fit clinical workflow and outcomes.

Clinical research and teaching institutions

Adopt the technology to evaluate new procedures and support training.

Strategia

The company’s strategy is to expand commercialization of its microwave ablation platform in the United States while continuing to build its international footprint. It is also broadening the product set with IRE-based products and an AI-powered robotic ablation system, aiming to deepen physician adoption and create a fuller procedure ecosystem. Regulatory clearances and sales coverage expansion are central to that plan because medical device adoption depends on both approvals and clinical uptake.

U.S. commercial expansionLyhyt aikaväli

The U.S. market can materially broaden adoption of the core MWA platform and raise credibility with physicians.

Product portfolio expansionKeskipitkä aikaväli

More device options can increase share of wallet and reduce dependence on a single technology.

Regulatory executionKeskipitkä aikaväli

Clearances are required to launch and scale new medical devices in target markets.

Global commercial footprintKeskipitkä aikaväli

International sales can diversify demand and support longer-term platform adoption.

Maantiede

Baird Medical is headquartered in Guangzhou, China, but it is also marketed as a U.S.-focused commercial platform for its microwave ablation systems. The company describes sales across multiple continents, with the United States and China both central to its operating footprint and regulatory strategy. This geography exposes the business to both U.S. and Chinese healthcare purchasing cycles, regulatory approvals, and cross-border execution risk.

Riskit

The company depends on successful regulatory approvals, physician adoption, and market access in both the United States and China. As a medical device business, it also faces product development risk, competitive technology risk, and the possibility that clinical or commercial uptake of new ablation platforms may be slower than planned. Cross-border operations add execution risk because reimbursement, compliance, and sales channels differ across markets.

Järjestetty vakavuuden mukaan
MatalaKohtalainenKorkeaMatalaKohtalainenKorkeaVaikutus →Todennäköisyys →Regulatory clearance delays1U.S. market execution risk2China expansion risk3Technology adoption risk4Development risk on new platforms5
Vaikutus on riskin vakavuus ja todennäköisyys sen toteutumisen todennäköisyys lähivuosina, molemmat arvioitu yhtiön raporttien perusteella. Numerot vastaavat listaa.
  1. Regulatory clearance delaysVaikutus: KorkeaTodennäköisyys: Kohtalainen

    New devices cannot scale commercially until the relevant health authorities clear them.

    Kohdistuu: New product pipeline

  2. U.S. market execution riskVaikutus: KorkeaTodennäköisyys: Kohtalainen

    The company is still building sales coverage and physician adoption in the U.S.

    Kohdistuu: Microwave ablation commercialization

  3. China expansion riskVaikutus: KorkeaTodennäköisyys: Kohtalainen

    The company explicitly identifies expansion in China as a key uncertainty.

    Kohdistuu: International sales

  4. Technology adoption riskVaikutus: KeskitasoTodennäköisyys: Kohtalainen

    Physicians may adopt competing ablation or surgical alternatives if outcomes or workflows are better.

    Kohdistuu: Core MWA platform

  5. Development risk on new platformsVaikutus: KeskitasoTodennäköisyys: Kohtalainen

    IRE-based and robotic systems require R&D success and validation before meaningful revenue contribution.

    Kohdistuu: R&D pipeline

Kysy Clarifolta: Baird Medical Investment Holdings Ltd

Kirjanpito

Harkinnanvaraiset erät
Revenue recognition timing

Device shipments, approvals, and launch timing can create uneven reported revenue across periods.

Vaikutus: Comparability across quarters

Stock-based compensation

The company reports substantial share-based compensation in adjusted EBITDA reconciliation.

Vaikutus: Affects profitability and adjusted metrics

Depreciation and amortization

Capitalized equipment and intangible assets flow through earnings over time.

Vaikutus: Impacts operating income and EBITDA bridge

Internal control / auditor change

A change in auditor and mention of material weaknesses increases reporting scrutiny.

Vaikutus: Confidence in reported numbers

Samankaltaisia listattuja yhtiöitä

Julkisesti listattuja yhtiöitä, joilla on samankaltainen liiketoiminta.

iTonic Holdings Ltd

ITOC · Electromedical & Electrotherapeutic Apparatus

Meihua International Medical Technologies Co., Ltd.

MHUAF · Surgical & Medical Instruments & Apparatus

IceCure Medical Ltd.

ICCM · Surgical & Medical Instruments & Apparatus

IR-Med, Inc.

Electromedical & Electrotherapeutic Apparatus

Pulse Biosciences, Inc

PLSE · Surgical & Medical Instruments & Apparatus

InMode Ltd.

INMD · Electromedical & Electrotherapeutic Apparatus

Päivitetty: 28.9.2026

Baird Medical Investment Holdings Ltd (BDMDW) liikevaihto, tulos ja tunnusluvut 2025 – Clarifo